argenx SE

Report Publication Announcement • Feb 5, 2016

argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference

Breda, the Netherlands / Ghent, Belgium, 5 February 2016- argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City (NY, USA) on Thursday, February 11, 2016 at 1:50pm ET.

The presentation will be webcast live and may be accessed via this link or by visiting the Company's website www.argenx.com. A replay of this webcast will be available for 90 days following the presentation.

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey. www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 243 40 70 info@argenx.com

Mark Swallow/David Dible Citigate Dewe Rogerson +44 207 282 2948 argenx@citigatedr.co.uk

Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200 beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law."Management's Discussion and Analysis of Financial Condition and Results of Operations"